GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old ...

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

The UK based drug firm GSK has agreed to pay up to $2.2bn (£1.7bn; €2bn) to settle claims that the heartburn drug ranitidine (previously marketed in the US as Zantac) caused cancer. The deal, ...

GSK said it expects to take a charge of £1.8 billion ($2.3 billion) in its third-quarter results in relation to the ...

智通财经获悉，葛兰素史克(GSK.US)周三宣布，该公司已同意支付高达22亿美元，以解决美国州法院提起的大多数诉讼，这些诉讼指控一种已停产的胃灼热药物Zantac会导致癌症。该公司说，与10家原告律师事务所达成的协议解决了约8万起案件，占美国全国州法 ...

The settlement, which is at the low end of Jefferies analysts’ $2 billion to $3.5 billion estimate, will resolve 93% of the ...

GSK shares jumped more than 5 per cent on Thursday after the pharma giant said it will pay up to £1.7billion to settle ...

GSK has agreed to pay $2.2bn to settle about 80,000 Zantac lawsuits in the US. In a statement released after the close of ...

Under the agreement, whose terms are confidential, GSK will make an "aggregate payment of up to $2.2 billion" to resolve ...

GSK has faced a long-running saga around Zantac, which is the brand name for the drug ranitidine. The product reduces the amount of acid the stomach makes, and was a best-seller in the UK and US ...